Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow . Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity demonstrating lymphoplasmacytic lymphoma (LPL) in the bone. Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring.
|Published (Last):||20 May 2014|
|PDF File Size:||11.81 Mb|
|ePub File Size:||13.88 Mb|
|Price:||Free* [*Free Regsitration Required]|
Despite the high incidence of HCV infection in these patients, a statistically significant association between HCV infection and WM has not been found. The light chain of the monoclonal eenfermedad is usually the kappa light chain.
Waldenström’s macroglobulinemia – Wikipedia
There is no single accepted treatment for WM. Differential diagnosis Table 3 is important for the exclusion of neoplasms potentially secreting monoclonal IgM and which can also present lymphocytes with lymphoplasmocytoid differentiation in the bone marrow. Curr Treat Options Oncol. Treatment includes the monoclonal antibody rituximabsometimes in combination with chemotherapeutic drugs such as chlorambucilcyclophosphamideor vincristine waldsnstrom with thalidomide.
Amyloidosis with IgM monoclonal gammopathies. Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstrom macroglobulinemia. This page was last edited on 20 Decemberat The Mayo Clinic has developed a therapeutic approach adapted to the clinical characteristics of the patient.
Current Opinion in Investigational Drugs. Monoclonal gammopathies and associated skin disorders. Hepatosplenic Angioimmunoblastic Enteropathy-associated T-cell lymphoma Peripheral T-cell lymphoma not otherwise specified Lennert lymphoma Subcutaneous T-cell lymphoma.
First-line therapy includes alkylating agents, purine analogs and monoclonal anti-CD20 antibodies. Mycosis fungoides Pagetoid reticulosis Granulomatous slack skin aggressive: In patients at low waldenwtrom, the average survival time is 12 years, and waldendtrom should involve low toxicity, preserving quality of life. The reuse of the first-line treatment is recommended enfegmedad the response to initial treatment was maintained without maintenance for at least 12 months. Paratrabecular infiltration; Centrocytes small cells with “cleaved” nuclei and reduced cytoplasm and centroblasts large cells with round or oval nuclei, vesicular chromatin, and low basophilic cytoplasm.
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. Guidelines on the management of Waldenstrom macroglobulinaemia. The treatment of asymptomatic patients does not improve their quality of life and survival; 3 biannual clinical observation is the recommended option in these cases if hematologic function is preserved.
Waldenstroom IgM can also connect nonspecifically to multiple antigens of the peripheral nerves, triggering axonal dnfermedad. In relation to the mechanisms involved in the pathophysiology of WM, the blocking of immunoglobulin isotype switching and the role of cytokines is noteworthy. The main reasons for choosing this regimen in these patients are the good treatment tolerance, reduced myelosuppression and the lack of toxicity for stem cells.
The new World Health Organization WHO classification, however, places WM under the category of lymphoplasmacytic lymphomas, itself a subcategory of the indolent low-grade non-Hodgkin lymphomas.
Recently, autologous bone marrow transplantation has been added to the available treatment options. Malignant lymphoma of the transverse colon associated with macroglobulinemia. In WM, medullary infiltrate consists of a monoclonal cellular population of small B-lymphocytes, in different maturation stages: How I treat Waldenstrom macroglobulinemia.
Services on Demand Journal. Waldestrom follow-up of IgM monoclonal gammopathy of undetermined significance.
Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Chemistry tests include lactate dehydrogenase LDH levels, uric acid levels, erythrocyte sedimentation rate ESRkidney and liver function, total protein levels, and an albumin-to-globulin ratio.
Results from characterization studies of urinary immunoglobulins indicate that light chains Bence Jones proteinusually of the kappa type, are found in the urine. ETIOLOGY Its etiology is unknown, but several studies suggest a possible causal relationship with autoimmune diseases, exposure to environmental factors and chronic antigenic stimulation, such as infection with the hepatitis C virus HCV.
Rituximab monoclonal anti-CD20 antibody: Beta-2 microglobulin is elevated in proportion to tumor enfermedaf. The symptoms of malabsorption, diarrhea, obstipation or bleeding may indicate involvement of the gastrointestinal tract. A low white blood cell enfemredadand low platelet count in the blood may be observed.
Although believed to be a sporadic disease, studies have shown increased susceptibility within families, indicating a genetic component. Signs and symptoms enfsrmedad WM include weaknessfatigueweight lossand chronic oozing of blood from the nose and gums.
J Dtsch Dermatol Ges. There are genetic factorswith first-degree relatives of WM patients shown to have a highly increased risk of also developing the disease. Type II cryoglobulinemia mono and polyclonal is characterized by the deposition of monoclonal Waldenatrom IgG immunocomplexes at the level of blood vessels, with consequent activation of the complement.
Thus, in most cases, the neoplastic B cells present somatic hyper-mutation in the genes coding the hypervariable regions of the immunoglobulin heavy chains V H genes. Evidence of anemia, constitutional symptoms, hyperviscosity, swollen lymph nodesor enlargement of the liver and spleen that can be attributed to an underlying lymphoproliferative disorder.
Pulmonary manifestations of Waldenstrom macroglobulinemia.